Literature DB >> 2539060

Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway.

J Elmgreen1, I Ahnfelt-Rønne, O H Nielsen.   

Abstract

The effect of auranofin on human neutrophil (PMN) 5-lipoxygenase activity and leucotriene B4 (LTB4) chemotaxis was investigated. [1-14C]Arachidonic acid was incorporated into the purified cells until steady state conditions were obtained. After preincubations with serial dilutions of auranofin arachidonic acid release and metabolism were stimulated with calcium ionophore A23187. The radioactive eicosanoids released were extracted and separated by thin layer chromatography, followed by autoradiography and quantitative laser densitometry. Chemotaxis of PMNs towards LTB4 was measured in a modified Boyden chamber. Auranofin showed dose dependent inhibition of both the 5-lipoxygenase pathway (IC50 17.4 X 10(-6) mol/l) and of chemotaxis (IC50 45 X 10(-6) mol/l). The release of arachidonic acid from phospholipids was unaffected in the concentration range tested (1-1000 mumol/l). Inhibition of both neutrophil motility and cellular synthesis of proinflammatory eicosanoids may thus contribute to the beneficial clinical effects of auranofin in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539060      PMCID: PMC1003699          DOI: 10.1136/ard.48.2.134

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  On the nature of the 5-lipoxygenase reaction in human leukocytes: characterization of a membrane-associated stimulatory factor.

Authors:  C A Rouzer; T Shimizu; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

2.  Modulation of neutrophil functions by auranofin. Studies on effects in vitro and in rheumatoid arthritis patients.

Authors:  I Hafström; A M Udén; J Palmblad
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

3.  Leukotriene B4 is a complete secretagogue in human neutrophils: a kinetic analysis.

Authors:  C N Serhan; A Radin; J E Smolen; H Korchak; B Samuelsson; G Weissmann
Journal:  Biochem Biophys Res Commun       Date:  1982-08       Impact factor: 3.575

4.  Activation of neutrophils and the lesions of rheumatoid arthritis.

Authors:  G Weissmann
Journal:  J Lab Clin Med       Date:  1982-09

5.  Evaluation of inhibitors of eicosanoid synthesis in leukocytes: possible pitfall of using the calcium ionophore A23187 to stimulate 5' lipoxygenase.

Authors:  J A Salmon; L C Tilling; S Moncada
Journal:  Prostaglandins       Date:  1985-03

6.  Polymorphonuclear granulocytes in rheumatic tissue destruction. III. an electron microscopic study of PMNs at the pannus-cartilage junction in rheumatoid arthritis.

Authors:  W Mohr; H Westerhellweg; D Wessinghage
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

7.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

8.  Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis.

Authors:  L B Klickstein; C Shapleigh; E J Goetzl
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis.

Authors:  E M Davidson; S A Rae; M J Smith
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

10.  Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4. Identification of a subset of high affinity receptors that transduce the chemotactic response.

Authors:  D W Goldman; E J Goetzl
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more
  5 in total

1.  Auranofin and its combination with LTB4 influences ATP level and migration of human polymorphonuclear cells in vitro.

Authors:  G Partsch; M Matucci-Cerinic
Journal:  Inflammation       Date:  1995-06       Impact factor: 4.092

2.  Potentiation and inhibition of migration of human neutrophils by auranofin.

Authors:  J G Elferink; B M de Koster
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

3.  Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor of Blastocystis Subtype 1, 4, and 7 Isolates.

Authors:  John Anthony Yason; Kristine Anne Ru Ping Koh; Kevin Shyong Wei Tan
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  Super-Low Dose Lipopolysaccharide Dysregulates Neutrophil Migratory Decision-Making.

Authors:  Brittany P Boribong; Mark J Lenzi; Liwu Li; Caroline N Jones
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

5.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.